Anvisa
Anvisa approves cannabis cultivation for medical purposes
An Ruwaito ta hanyar AI Hoton da AI ya samar
The National Health Surveillance Agency (Anvisa) approved, on January 28, 2026, resolutions allowing cannabis cultivation for health treatments and research, along with new administration routes and plant imports. This step marks progress in the national production chain, easing access to plant-derived medicines. The changes broaden options for patients with severe illnesses while upholding strict restrictions.
Brazil's Anvisa banned on Wednesday (29) the manufacturing, distribution, sale, and promotion of all cosmetics from Henlau Química, including brands Sunlau, Wurth, and Needs. The action followed an inspection revealing unauthorized formulas and regulatory breaches. The agency ordered product recalls.
An Ruwaito ta hanyar AI
Brazil's Federal Revenue seized over 700 shipments containing about 1 ton of banned peptides at Viracopos International Airport in Campinas, SP, from January to March 2026. The substances, mainly from China and Hong Kong, targeted weight loss and other uses without Anvisa approval. The operation underscores health risks and a growing illegal market.